Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3032 Lung Side and Site: The Importance of Location and the Prognostic Implication in Lung Neuroendocrine Tumors

Introduction: Lung neuroendocrine tumors (NET) are classified as typical (TC) and atypical carcinoids (AT), according to their mitotic count and the presence of necrosis. However, a role for tumor side (right vs left) and location (central vs peripheric) has not been established so far.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: La Salvia A

Authors: La Salvia A, Trevisi E, Brizzi M, Espinosa Olarte P, Enguita A,

Keywords: Lung neuroendocrine tumors, tumor side (left versus right), tumor site (peripheric versus central), prognostic factors, survival,

#3011 Added Prognostic Value of Molecular Imaging Biomarkers over Proliferation Index in Typical Lung Carcinoid: An FDG PET and SSTR Imaging Study

Introduction: Typical lung carcinoids(TCs)are rare tumors with good,although heterogeneous,prognosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Briganti V

Authors: Briganti V, Berti V, Abenavoli E, Linguanti F, Ciaccio A,

Keywords: typical lung carcinoid, FDG PET, SSTR imaging, MTV, TLG,

#2745 Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids

Introduction: Lung carcinoids (LCs) are rare and slow growing primary lung neuroendocrine tumors. The WHO classify LCs into atypical and typical carcinoids. Recent studies have shown that the reproducibility of LCs classification and its prognostic efficacy have high interobserver variability

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Laddha S

Authors: Laddha S, da Silva E, Robzyk K, Untch B, Ke H,

Keywords: MEN1, Lung Carcinoid, Lung Cancer, ASCL1, Novel Molecular Subtypes, Genotype to Phenotype, Integrative Genomic Analysis, Biomarkers, Genomics and Epigenomics,

#1725 Safety of Lanreotide 120 mg ATG (LAN) in Combination with Metformin (MET) in Patients (pts) with Progressive Advanced Well-Differentiated (WD) Gastro-Intestinal (GI) or Lung Carcinoids. A Pilot, One-Arm, Open-Label, Prospective Study: The MetNET-2 Trial

Introduction: Anti proliferative effect of LAN ATG 120 mg has been investigated in 204 GI-NET pts in Clarinet study with a 53% reduction in risk of death/progression vs placebo. An increasing number of trials have associated MET with better outcome in cancer pts due to a reduction of insulin/IGF1 levels and modulation of AMPK and TSC1-2/mTOR. The retrospective PRIME-net study conducted on 445 Italian pts, suggest that addition of MET to everolimus and/or SSA provides clinical benefit in diabetic pancreatic NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: pusceddu s

Authors: Prinzi N, Femia D, Concas L, Lo Russo G, Vernieri C,

Keywords: lanreotide, metformin,

#1650 Lung Carcinoid: Role of NSE and Imaging Techniques in Long-Term Follow-Up of Malignancy Recurrence

Introduction: Typical and atypical Lung Carcinoids (LC) are rare neuroendocrine tumors usually characterized by good prognosis. Malignancy recurrence (MR) is uncommon but may occur even after several years; a close long-term follow-up is required.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Zanata I

Authors: Zanata I,

Keywords: lung carcinoid, follow-up, nse, imaging,